Impact of relatively new chemotherapeutic agents on the outcome of Egyptian patients with advanced malignant pleural mesothelioma

Open access

Abstract

Purpose: Patients with malignant pleural mesothelioma (MPM) are well known to have poor response to chemotherapy. The aim of this work was to evaluate the efficacy and safety of new chemotherapeutic agents for the treatment of Egyptian MPM patients.

Patients and methods: The first study was a non-randomised, open-label trial. It included 34 eligible patients who were assigned to receive either cisplatin–pemetrexed or pemetrexed alone if cisplatin was contraindicated for a maximum of eight cycles. In the second trial, 21 chemo-naive patients with histologically proven advanced MPM were included. They received cisplatin and raltitrexed for a maximum of six cycles.

Results: In the first trial, the median age was 43.5 years (range 25–69), partial response (PR) was achieved in 37.5%, stable disease (SD) in 50%. Median time to progression (TTP) and overall survival (OS) were 7 and 14 months, respectively. Survival at 1 year was 64.7%. No toxicity was observed in 17.6% of patients and grade 3–4 toxicity was evident in 11.8% (neutropenia), 8.8% (anaemia) and 2.9% (vomiting and diarrhoea) of patients. In the second trial, median age was 46 years (range 19–71), PR was achieved in 23.2% and one CR was reported. SD was noticed in 61.9% of patients. Median TTP and OS were 6 and 12 months, respectively. Survival at 1 year was 51.6%.

Conclusion: Both cisplatin–pemetrexed and cisplatin–raltitrexed are effective and safe regimens in the treatment of MPM.

[1] Gaafar R, Aly Ely Eldin N; Epidemic of mesothelioma in Egypt, Lung Cancer, 2005, 49S1, S17-S20.

[2] Abou El-Kasem F, Gaafar R, Abdel-Rahman A, Abdel-Baki H, Hassan N. Malignant pleural mesothelioma: analysis of 100 consecutive patients. Lung Cancer 2004, 45(3):s67.

[3] Porret E, Madelaine J, Galateau-Salle F, et al. Epidemiology, molecular biology, diagnostic and therapeutic strategy of malignant pleural mesothelioma in 2007-an update. Rev Mal Respir 2007; 24:6S157-64. [PubMed]

[4] Van Schil PE, Baas P, Gaafar R, et al. Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. Eur Respir J 2010;36:1362-9.

[5] Hillerdal G, Sorensen JB, Sundstrom S, et al. Treatment of malignant pleural mesothelioma with carboplatin, liposomized doxorubicin, and gemcitabine: a phase II study. J Thorac Oncol 2008; 3:1325-[6] van Meerbeeck JP, Baas P, Debruyne C, et al: EORTC Lung Cancer Group. A phase II EORTC study of temozolomide in patients with malignant pleural mesothelioma. Eur J Cancer 2002, 38, 779-783.

[7] Habib EE, Fahmy ES. Chemotherapy management of malignant pleural mesothelioma: a phase II study comparing two popular chemotherapy regimens. Clin Transl Oncol. 2013 [Epub ahead of print] [PubMed]

[8] van Meerbeeck J, Debruyne C, van Zandwijk N, et al: Paclitaxel for malignant pleural mesothelioma: A phase II studies of the EORTC Lung Cancer Cooperative Group. Br J Cancer, 1996, 74, 961-963.

[9] Scherpereel A, Astoul P, Baas P, et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J 2010; 35: 479-95.

[10] Sahmoud T, Postmus PE, van Pottelsberghe C, et al: G. Etoposide in malignant pleural mesothelioma: Two phase II trials of the EORTC Lung Cancer Cooperative Group. Eur J Cancer,1997, 33, 2211-2115.

[11] Ellis P, Davies AM, Evans WK, etal: The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systemic review and practice guide lines. J Thoracic Oncol, 2006, 1(6), 591-601.

[12] Shin DM, Scagliotti GV, Kindler HL, et al: A phase II trial of pemetrexed in malignant pleural mesothelioma (MPM) patients: Clinical outcome, role of vitamin supplementation, respiratory symptoms and lung function. Proc Am Soc Clin Oncol, 2002, 21, 294 (abstr 1175).

[13] Vogelzang N, Rusthoven J., Symanowski J., etal phase III Study of Pemetrexed in Combination With CisplatinVersus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma, J Clin Oncol 2003, 21, 2636-2644.

[14] Baas P, Ardizzoni A, Grossi F, et al: EORTC Lung Cancer Group: The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: An EORTC phase II study (08992). Eur J Cancer 2003, 39, 353-357.

[15] Fizazi K, Doubre H, Le Chevalier T, et al: Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: Results of a phase II study. J Clin Oncol 2003, 21, 349- 354.

[16] van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase IIIstudy of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005;23: 6881-9.

[17] Ceresoli GL, Zucali PA, Favaretto AG, et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 2006; 24:1443.

[18] Castagneto B, Botta M, Aitini E, et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol 2008; 19:370.

[19] Santoro A, O’Brien ME, Stahel RA, et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol 2008; 3:756.

[20] Laurie SA, Gupta A, Chu Q, et al. Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. The NCIC Clinical Trials Group. J Thorac Oncol 2011; 6:1950-4.

[21] Kindler HL, Karrison TG, Gandara DR, et al. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol 2012; 30:2509-15.

[22] Zucali PA, Ceresoli GL, De Vincenzo F, et al. Advances in the biology of malignant pleural mesothelioma. Cancer Treat Rev 201; 37:543-58. [PubMed]

Journal Information

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 148 145 11
PDF Downloads 70 68 3